RxDoctor Payments DataLook up a doctor →

Tyler Nelson, MD

Internal Medicine · Bryant, ARNPI 1306814546

Payments from drug & device makers

$8,961in general payments, 2019–2025

Across 600 payments — averaging $14.93 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$2K
  • Amgen$965
  • AstraZeneca$833
  • Pfizer$449
  • Novo Nordisk$407
  • Takeda Pharmaceuticals U.S.A., Inc.$358
  • plus $4K from 42 others

What the payments were for

  • Food & beverage$8,961100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$8,961 in reported general payments places this provider in the 90th percentile of 614 internal medicine providers in Arkansas.

See all internal medicine providers in Arkansas

Medicare billing

Part B allowed, 2024
$129,204
Medicare patients
400
Services billed
2,196

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide136$157,160
MounjaroTirzepatide45$43,771
Trelegy ElliptaFluticasone/Umeclidin/Vilanter57$43,189
VraylarCariprazine Hcl23$32,817
Soliqua 100-33Insulin Glargine/Lixisenatide32$31,543
JardianceEmpagliflozin20$29,008
EliquisApixaban31$28,163
ArexvyRsvpref3 Antigen/As01e/Pf94$27,734
ShingrixVaricella-Zoster Ge/As01b/Pf117$24,429
MyrbetriqMirabegron24$20,860
Repatha SureclickEvolocumab23$16,145
GemtesaVibegron29$16,131
Toujeo SolostarInsulin Glargine,hum.Rec.Anlog27$15,183
Janumet XrSitagliptin Phos/Metformin Hcl11$13,824
TrintellixVortioxetine Hydrobromide12$13,627

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$407$157,160136 claims
GSKTrelegy Ellipta, Arexvy, Shingrix, Anoro Ellipta, Breo Ellipta$166$116,039303 claims
Lilly USA, LLCMounjaro$299$43,77145 claims
AbbVieVraylar, Synthroid$1,587$36,08754 claims
Sanofi-aventis U.S. LLCSoliqua 100-33$199$31,54332 claims
Boehringer IngelheimJardiance$339$29,00820 claims
PfizerEliquis$449$28,16331 claims
MerckJanumet Xr, Belsomra$251$25,94239 claims
Astellas Pharma US IncMyrbetriq$101$20,86024 claims
Sumitomo Pharma America, Inc.Gemtesa$31$16,13129 claims
AstraZenecaBreztri Aerosphere, Symbicort$833$14,78233 claims
Takeda Pharmaceuticals U.S.A., Inc.Trintellix$358$13,62712 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 614 internal medicine providers in Arkansas.

Other internal medicine in Bryant

See the full list for Arkansas

Where these figures come from

Is this you, or does something look wrong? →